Physician profile
Mark Eichenbaum
NPI 1871764977
$2,289.86
in general payments reported to CMS, 2019-2025
23 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.08 · 2020: $238 · 2021: $470 · 2022: $223 · 2023: $535 · 2024: $419 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.50 | 2020-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $309.03 | 2019-2025 | |
| Lilly USA, LLC | $297.77 | 2021-2025 | Mounjaro, Amyvid, Trulicity |
| Janssen Pharmaceuticals, INC | $176.60 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $150.05 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $132.38 | 2020-2025 | Trelegy Ellipta |
| Abbvie INC. | $117.12 | 2021-2025 | |
| Astellas Pharma US INC | $98.25 | 2020-2023 | Myrbetriq |
| Pfizer INC. | $96.69 | 2021-2025 | |
| Amgen INC. | $94.15 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $73.53 | 2019-2023 | Eliquis |
| Biogen, INC. | $68.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $52.83 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $38.98 | 2023-2025 | Gemtesa |
| Allergan, INC. | $38.63 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $34.99 | 2020 | |
| Corium, LLC | $32.99 | 2023 | Adlarity |
| Lundbeck LLC | $29.36 | 2024 | Rexulti |
| Insmed, INC. | $27.36 | 2025 | Brinsupri, Arikayce |
| Eisai INC. | $22.37 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.25 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $20.50 | 2025 | Quviviq |
| Abbott Laboratories | $16.90 | 2023 | Mitraclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Eichenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.